Market Access Impact US [Growth Hormone Deficiency] [Report Updated: 01062017] Prices from USD $5145

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

What stops doctors from prescribing your brand? It may be more than one thing

Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of them. According to the endocrinologists we surveyed, that's a problem with no single solution; many of them experience as many as 3 different barriers with any given brand.

Find out which barriers cost your brand the most market share, which competitors are taking it from you, and what you can do to win it back, in Market Access Impact: GHD US.

Based on a survey of 100 adult and paediatric endocrinologists, the report covers 7 major therapies from Aeterna Zentaris, Eli Lilly, EMD Serono, Ferring, Novo Nordisk, Pfizer, Roche, and Sandoz. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Top Takeaways

Most brands lose out: While every brand wins and loses share because of barriers, 4 of the 7 surveyed brands see a net loss.
Barriers skew the top of the market: The 3rdplace brand takes a 6% market share hit. Without barriers, it would rocket up to 1stplace.
One brand leads the table. Another can't catch a break: Find out which brand sees a net share gain from every other surveyed brand, and which one sees a net loss to every other brand.
No single barrier is to blame: 25% to nearly 40% of surveyed doctors experience 3 or more barriers with the surveyed brands.
Some brands have a perception problem: Up to 20% of doctors either wouldn't consider prescribing three of the surveyed brands, or haven't heard of them at all.
Cost is a huge problem for one brand: Over 40% of doctors experience cost barriers with this brand. That's at least 10% more than any competitor.

Insight into 7 Major GHD Treatments

Genotropin somatropin; Pfizer
Humatrope somatropin; Eli Lilly
Norditropin somatropin; Novo Nordisk
NutropinAq somatropin; Roche
Omnitrope somatropin; Sandoz
Saizen somatropin; EMD Serono/Aeterna Zentaris
Zomacton somatropin; Ferring

Exploring Market Access Barriers

Market Access Impact: GHD US explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don't, but would consider it?
Why don't doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 USbased adult and paediatric endocrinologists, chosen from the largest community of validated physicians in the world

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with GHD in total in the last month

We conducted the survey between May 2nd and 10th, 2017.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: Market Access Impact US [Growth Hormone Deficiency] [Report Updated: 01062017] Prices from USD $5145


More From BioPortfolio on "Market Access Impact US [Growth Hormone Deficiency] [Report Updated: 01062017] Prices from USD $5145"

Quick Search


Relevant Topics

Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...